FDA's Pazdur Jumps Over To New 'Moonshot' Role
This article was originally published in The Pink Sheet Daily
Executive Summary
Creation of agency's new Oncology Center of Excellence means the Office of Hematology and Oncology Products, often seen as FDA's model product review shop, needs new leadership – at least temporarily.
You may also be interested in...
OCE 2.0? US FDA Leadership Change May Present Opportunity To Grant Full Review Authority
With a new commissioner expected next year, a restructuring may allow the Oncology Center of Excellence to assume sign-off authority for biologics and devices along with drugs.
US FDA May Create Immunology, Neuroscience Centers Of Excellence
Commissioner Gottlieb says new centers would follow template of Oncology Center of Excellence.
US FDA's Oncology Division Wants To Know About Your Pipeline, Not Just Your NDAs
Oncology Center of Excellence Director Richard Pazdur says agency invites sponsors to present about molecules under development to learn more about future plans.